Barbara Osborne to Antineoplastic Agents
This is a "connection" page, showing publications Barbara Osborne has written about Antineoplastic Agents.
Connection Strength
0.598
-
Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med. 2006 Dec; 6(8):905-18.
Score: 0.184
-
Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021 02; 20(2):125-144.
Score: 0.122
-
Canakci M, Singh K, Munkhbat O, Shanthalingam S, Mitra A, Gordon M, Osborne BA, Thayumanavan S. Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine-Loaded Nanogels. Biomacromolecules. 2020 06 08; 21(6):2473-2481.
Score: 0.117
-
Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, Minter LM, Osborne BA, Miele L, Golde TE. ?-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med. 2017 07; 9(7):950-966.
Score: 0.096
-
Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008 Sep 01; 27(38):5124-31.
Score: 0.052
-
Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010 Jun 15; 16(12):3141-52.
Score: 0.015
-
Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, Kast WM, Stone PJ, Santos L, Loredo A, Lendahl U, Sonenshein G, Osborne B, Qin JZ, Pannuti A, Nickoloff BJ, Miele L. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008 Oct 02; 27(44):5833-44.
Score: 0.013